Neoadjuvant Treatment in Resectable Pancreatic Cancer. Is It Time for Pushing on It?

Pancreatic resection still represents the only curative option for patients affected by pancreatic ductal adenocarcinoma (PDAC). However, the association with modern chemotherapy regimens is a key factor in improving the inauspicious oncological outcome. The benefit of neoadjuvant treatment (NAT) fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Vivarelli, Marco, Mocchegiani, Federico, Nicolini, Daniele, Vecchi, Andrea, Conte, Grazia, Dalla Bona, Enrico, Rossi, Roberta, Benedetti Cacciaguerra, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9195424/
https://www.ncbi.nlm.nih.gov/pubmed/35712487
http://dx.doi.org/10.3389/fonc.2022.914203

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9195424/
https://www.ncbi.nlm.nih.gov/pubmed/35712487
http://dx.doi.org/10.3389/fonc.2022.914203

Ejemplares similares